Cargando…

Rectal vs. sublingual misoprostol in cesarean section: Three‑arm, randomized clinical trial

BACKGROUND: Misoprostol is a myometrial stimulant with uterotonic properties and can be administered rectally, vaginally, or sublingually. Numerous studies have investigated the effect of misoprostol on the prevention and treatment of PPH (postpartum hemorrhage) after vaginal delivery, but its use t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagheri, Fatemeh Zahra, Azadehrah, Mahboobeh, Shabankhani, Bizhan, Nasiri Formi, Ebrahim, Akbari, Hooshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797813/
https://www.ncbi.nlm.nih.gov/pubmed/35178212
http://dx.doi.org/10.22088/cjim.13.1.84
_version_ 1784641643957190656
author Bagheri, Fatemeh Zahra
Azadehrah, Mahboobeh
Shabankhani, Bizhan
Nasiri Formi, Ebrahim
Akbari, Hooshang
author_facet Bagheri, Fatemeh Zahra
Azadehrah, Mahboobeh
Shabankhani, Bizhan
Nasiri Formi, Ebrahim
Akbari, Hooshang
author_sort Bagheri, Fatemeh Zahra
collection PubMed
description BACKGROUND: Misoprostol is a myometrial stimulant with uterotonic properties and can be administered rectally, vaginally, or sublingually. Numerous studies have investigated the effect of misoprostol on the prevention and treatment of PPH (postpartum hemorrhage) after vaginal delivery, but its use to control PPH during cesarean section has not been widely studied. METHODS: In this clinical trial study, 180 pregnant women who were candidates for cesarean section were included in the study. They were divided into 3 groups of 60 people (sublingual misoprostol group, rectal misoprostol group, control group). In all three groups, the volume of blood lost was recorded in the checklist at the end of surgery. Data were entered into SPSS software and analyzed. RESULTS: The mean bleeding in the control group was 225.4±63.9, while it was 137.9±33.8 and 118.9±28.5 in the sublingual misoprostol group and rectal misoprostol group, respectively. We had significantly more bleeding in the control group (p<0.001) compared to the other two groups. CONCLUSION: These results confirm the positive effect of misoprostol in reducing bleeding and show the superiority of using rectal misoprostol compared to other methods of reducing bleeding during cesarean section.
format Online
Article
Text
id pubmed-8797813
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Babol University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-87978132022-02-16 Rectal vs. sublingual misoprostol in cesarean section: Three‑arm, randomized clinical trial Bagheri, Fatemeh Zahra Azadehrah, Mahboobeh Shabankhani, Bizhan Nasiri Formi, Ebrahim Akbari, Hooshang Caspian J Intern Med Original Article BACKGROUND: Misoprostol is a myometrial stimulant with uterotonic properties and can be administered rectally, vaginally, or sublingually. Numerous studies have investigated the effect of misoprostol on the prevention and treatment of PPH (postpartum hemorrhage) after vaginal delivery, but its use to control PPH during cesarean section has not been widely studied. METHODS: In this clinical trial study, 180 pregnant women who were candidates for cesarean section were included in the study. They were divided into 3 groups of 60 people (sublingual misoprostol group, rectal misoprostol group, control group). In all three groups, the volume of blood lost was recorded in the checklist at the end of surgery. Data were entered into SPSS software and analyzed. RESULTS: The mean bleeding in the control group was 225.4±63.9, while it was 137.9±33.8 and 118.9±28.5 in the sublingual misoprostol group and rectal misoprostol group, respectively. We had significantly more bleeding in the control group (p<0.001) compared to the other two groups. CONCLUSION: These results confirm the positive effect of misoprostol in reducing bleeding and show the superiority of using rectal misoprostol compared to other methods of reducing bleeding during cesarean section. Babol University of Medical Sciences 2022 /pmc/articles/PMC8797813/ /pubmed/35178212 http://dx.doi.org/10.22088/cjim.13.1.84 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Bagheri, Fatemeh Zahra
Azadehrah, Mahboobeh
Shabankhani, Bizhan
Nasiri Formi, Ebrahim
Akbari, Hooshang
Rectal vs. sublingual misoprostol in cesarean section: Three‑arm, randomized clinical trial
title Rectal vs. sublingual misoprostol in cesarean section: Three‑arm, randomized clinical trial
title_full Rectal vs. sublingual misoprostol in cesarean section: Three‑arm, randomized clinical trial
title_fullStr Rectal vs. sublingual misoprostol in cesarean section: Three‑arm, randomized clinical trial
title_full_unstemmed Rectal vs. sublingual misoprostol in cesarean section: Three‑arm, randomized clinical trial
title_short Rectal vs. sublingual misoprostol in cesarean section: Three‑arm, randomized clinical trial
title_sort rectal vs. sublingual misoprostol in cesarean section: three‑arm, randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797813/
https://www.ncbi.nlm.nih.gov/pubmed/35178212
http://dx.doi.org/10.22088/cjim.13.1.84
work_keys_str_mv AT bagherifatemehzahra rectalvssublingualmisoprostolincesareansectionthreearmrandomizedclinicaltrial
AT azadehrahmahboobeh rectalvssublingualmisoprostolincesareansectionthreearmrandomizedclinicaltrial
AT shabankhanibizhan rectalvssublingualmisoprostolincesareansectionthreearmrandomizedclinicaltrial
AT nasiriformiebrahim rectalvssublingualmisoprostolincesareansectionthreearmrandomizedclinicaltrial
AT akbarihooshang rectalvssublingualmisoprostolincesareansectionthreearmrandomizedclinicaltrial